Management of antiretroviral therapy for HIV infection: Modelling when to change therapy

Antiviral Therapy

Volumn 3, Issue 3, 1998, Pages 147-158

  D'Aquila, Richard T ^a  

^a RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ARTICLE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MODEL; MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SYSTEM ANALYSIS; VIRUS LOAD;

ANTI-HIV AGENTS; GENOTYPE; HIV INFECTIONS; HUMANS; MONTE CARLO METHOD; PROBABILITY; RNA, VIRAL; TIME FACTORS;

EID: 17344370608     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the international AIDS Society-USA Panel. Journal of the American Medical Association 1997; 277:1962-1969.
2. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA & D'Aquila RT. Monitoring plasma human immunodeficiency virus RNA levels improves assessment of antiretroviral therapeutic response. Annals of Internal Medicine 1997; 126:929-938.
3. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 1998; 280:78-90.
4. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S & Richman DD. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. Journal of the American Medical Association 1998; 279:1984-1991.
5. Law AM & Kelton WD. Simulation Modeling and Analysis, 2nd edn, 1982. New York: McGraw-Hill.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM & Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
7. Perelson AS, Neumann AU, Markowitz M, Leonard JM & Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 195; 271:1582-1586.
8. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-123.
9. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-191.
10. Orenstein JM, Fox C & Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997; 276:1857-1861.
11. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P & Siliciano RF. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-188.
12. Vanhove GF, Schapiro JM, Winters MA, Merigan TC & Blaschke TF. Patient compliance and drug failure in protease inhibitor monotherapy. Journal of the American Medical Association 1996; 276:1955-1956.
13. de Jong MD, Veenstra J, Stilianakis NI, Schuurman R, Lange JM, de Boer RJ & Boucher CA. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of HIV-1 RNA load suppression by zidovudine. Proceedings of the National Academy of Sciences, USA 1996; 93:5501-5506.
14. Wein LM, D'Amato RM & Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. Journal of Theoretical Biology 1998; 192:81-98.
15. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CA, Leonard JM, Norbeck DW & Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine 1996; 2:760-766.
16. Patick AK, Kuritzkes D, Johnson VA, Shugarts D, Bakhtiari M, Potts KE, Farnsworth A, Anderson R, Koel JL, Hazelwood JD, Nail CD, Duran M, Markowitz M, Ho D & Richman D. Genotypic and phenotypic analyses of HIV-1 variants isolated from patients treated with nelfinavir and other HIV-1 protease inhibitors. Antiviral Therapy 1997; 2 (Suppl. 5):26 (Abstract 18).
17. Armitage P & Berry G. Statistical Methods in Medical Research, 2nd edn, 1987. New York: Blackwell Scientific Publications.
18. Richman DD, Grimes JM & Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes 1990; 8:743-746.